Developer docs
API playgroundTry for free, no card

Search company profiles

Agios Pharmaceuticals

Full company profile

uuid0000oat

Namestring
Agios Pharmaceuticals
Legal namestring
Agios Pharmaceuticals, Inc.
Websiteurl
agios.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Agios Pharmaceuticals is a publicly traded biopharmaceutical company (NASDAQ: AGIO) headquartered in Cambridge, Massachusetts, that develops oral therapies for rare hemolytic anemias and related rare diseases. After selling its oncology business to Servier for up to $2 billion in December 2020, the company pivoted to focus exclusively on cellular metabolism and rare blood disorders. Its commercial products — PYRUKYND and AQVESME, both formulations of the oral pyruvate kinase (PK) activator mitapivat — treat adults with pyruvate kinase deficiency (FDA-approved February 2022) and alpha- or beta-thalassemia (FDA-approved December 2025), respectively. The company's core scientific platform is built around PK activation, the mechanism by which mitapivat increases red blood cell ATP production, reduces 2,3-DPG levels, and improves red blood cell energy metabolism and lifespan in patients with hemolytic anemia.

The company's pipeline extends its cellular metabolism platform into adjacent indications, including tebapivat (a next-generation oral PK activator in Phase 2 for sickle cell disease and lower-risk MDS), cevidoplenib (an oral SYK inhibitor licensed from Oscotec in June 2026 for immune thrombocytopenia, with Phase 3 trials planned for H1 2028), AG-236 (an siRNA therapeutic targeting TMPRSS6 for polycythemia vera), and AG-181 (a phenylalanine hydroxylase stabilizer for phenylketonuria). Agios has also filed an sNDA seeking accelerated FDA approval for mitapivat in sickle cell disease, based on Phase 3 RISE UP data showing a 40.6% hemoglobin response rate versus 2.9% on placebo.

Agios generates revenue through direct U.S. product sales via specialty pharmacies and REMS-certified prescribers, supplemented by international royalty and milestone revenue from exclusive commercialization partners (Avanzanite Bioscience for 32 European countries and the UK/Switzerland; NewBridge Pharmaceuticals for the GCC region). AQVESME is priced at $425,000 per patient per year in the United States, with the U.S. thalassemia launch population estimated at approximately 4,000 patients and a global peak-year sales potential of $1 billion across multiple indications. Q1 2026 worldwide net product revenue was $20.7 million (up 138% year-over-year from $8.7 million), with 242 prescriptions written for AQVESME by quarter-end. The company ended Q1 2026 with $1.0 billion in cash and marketable securities against an annual operating cash burn of approximately $385 million.

Short descriptiontext

Agios Pharmaceuticals is a biopharmaceutical company developing oral pyruvate kinase activators and related therapies for rare hemolytic anemias, including pyruvate kinase deficiency, thalassemia, and sickle cell disease. It commercializes PYRUKYND and AQVESME and pursues pipeline expansion via licensing and partnerships.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rare disease therapeutics, hemolytic anemia treatments, pyruvate kinase activators, biopharmaceutical medicines, cellular metabolism drugs
Industry1 code
PRIMARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Medicinal and Botanical Manufacturing325411
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Rare Disease Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Sales (PYRUKYND/AQVESME)
TypeOne Time License
Description

Agios generates revenue from direct product sales of mitapivat under two brand names: PYRUKYND for pyruvate kinase deficiency (approved in US 2022, EU 2022, UAE, KSA) and AQVESME for thalassemia (approved in US December 2025, EU May 2022). Revenue is generated through prescription sales via specialty pharmacies and healthcare providers, with 242 prescriptions written by Q1 2026.

ainvest.com
2Licensing and Partnership Revenue
TypeLicensing Royalties
Description

Agios receives milestone payments and royalties from commercial partners including Avanzanite Bioscience (Europe) and NewBridge Pharmaceuticals (GCC), who hold exclusive rights to commercialize mitapivat in their respective territories under revenue-sharing or royalty arrangements.

seekingalpha.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1AQVESME (mitapivat for thalassemia) - Annual wholesale pricing
ModelSubscriptionBilling cadenceAnnual
Notes

$425,000 per year for AQVESME (mitapivat) in the United States. Launch population estimated at 4,000 patients in the US with addressable thalassemia population. Global peak-year sales potential estimated at $1 billion across multiple indications.

fiercepharma.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Agios Pharmaceuticals develops and commercializes oral small-molecule therapeutics for rare hemolytic anemias, led by its first-in-class pyruvate kinase (PK) activator mitapivat marketed as PYRUKYND for pyruvate kinase deficiency and AQVESME for alpha- and beta-thalassemia. The company supplements these approved products with a pipeline of next-generation PK activators (tebapivat), a SYK inhibitor (cevidoplenib), an siRNA candidate (AG-236), and a PAH stabilizer (AG-181), supported by patient access programs such as MyAgios and the Global Managed Access Program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 138% year-over-year revenue growth in Q1 2026 ($20.7M vs $8.7M Q1 2025)
+6 more records
Product overview1 text field

Agios Pharmaceuticals is a biopharmaceutical company developing a portfolio of therapies for rare diseases, particularly hemolytic anemias. The company's core approved products include PYRUKYND (mitapivat) for pyruvate kinase deficiency and AQVESME (mitapivat) for thalassemia, both oral pyruvate kinase activators that improve red blood cell energy metabolism. The pipeline includes next-generation candidates: Tebapivat (next-generation PK activator) for sickle cell disease and MDS, Cevidoplenib (SYK inhibitor) for immune thrombocytopenia, AG-236 for polycythemia vera, and AG-181 for phenylketonuria. Patient support services include the MyAgios program and Global Managed Access Program. The company leverages expertise in cellular metabolism to advance these rare disease therapies.

Product and service6 records
1PYRUKYND (mitapivat)
CategoryApproved Rare Disease Drug
Description

First-in-class oral pyruvate kinase (PK) activator approved for treating adults with pyruvate kinase deficiency. Increases ATP production and decreases 2,3-DPG in red blood cells to improve red blood cell energy metabolism and lifespan. Distributed in the U.S. through REMS-certified physicians and in Europe via Avanzanite Bioscience.

2AQVESME (mitapivat)
CategoryApproved Rare Disease Drug
Description

Oral pyruvate kinase activator approved by the FDA in December 2025 for treating anemia in adults with alpha- or beta-thalassemia; the only FDA-approved treatment for both non-transfusion-dependent and transfusion-dependent thalassemia. U.S. annual wholesale pricing is $425,000.

3Tebapivat (AG-946)
CategoryPipeline Drug Candidate
Description

Next-generation oral pyruvate kinase activator in Phase 2 development for sickle cell disease and lower-risk myelodysplastic syndromes (MDS); designed as an improved follow-on to mitapivat.

4Cevidoplenib
CategoryPipeline Drug Candidate
Description

Next-generation oral SYK inhibitor licensed from Oscotec for treating immune thrombocytopenia (ITP); Agios plans Phase 3 development in H1 2028 with peak US sales potential estimated at up to $1 billion.

5MyAgios Patient Support Program
CategoryPatient Support Service
Description

Comprehensive patient support services program providing access support, prescription fulfillment, financial assistance, disease education, and community connections for eligible patients on Agios medicines, with dedicated Patient Support Managers.

6Global Managed Access Program (GMAP)
CategoryPatient Access Program
Description

Program providing a pathway for patients to obtain access to PYRUKYND in countries where the medicine is not yet widely available, evaluating requests in consultation with qualified treating healthcare providers.

Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-19
Description

Co-hosting partnership for the 7th Annual 24-Hour World Sickle Cell Day Marathon on June 19, 2026, themed 'Closing the Survival Gap: Equity in Sickle Cell Care.' Agios serves as Advocate Sponsor alongside Community Sponsor Fulcrum Therapeutics. The virtual event brings together patients, caregivers, advocates, healthcare professionals, researchers, and policymakers to address disparities in diagnosis, treatment, and mental health services for sickle cell disease.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

Exclusive global license agreement with South Korea-based Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for treating immune thrombocytopenia (ITP). Agios paid $25 million upfront with potential additional payments of up to $140 million in development and regulatory milestones plus tiered royalties on future net sales. Agios assumes full responsibility for future development and commercialization costs, with plans to advance cevidoplenib into Phase 3 development for ITP in H1 2028. Peak US sales potential estimated at up to $1 billion.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-22
Description

Exclusive partnership agreement with Amsterdam-based Avanzanite Bioscience B.V. for commercialization and distribution of PYRUKYND (mitapivat) across the European Economic Area, United Kingdom, and Switzerland. Avanzanite commercialized the drug following EU approval for thalassemia in May 2026. This is Avanzanite's fourth rare disease launch in Europe. The partnership was originally signed in June 2025.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Partnership with NewBridge Pharmaceuticals for commercialization of PYRUKYND in the Gulf Cooperation Council (GCC) region, covering Saudi Arabia and other GCC countries. The partnership was established to expand access to mitapivat in the Middle East market, pending regulatory approvals in those territories.

5Global Alliance of Sickle Cell Disease Organizations (GASCDO)
Strategic tierMinorTypeGTM or Marketing Partner
Description

Co-hosting partnership with GASCDO for the 7th Annual 24-Hour World Sickle Cell Day Marathon, a free virtual event streamed live for 24 hours to address disparities in sickle cell disease care globally.

ainvest.com
Strategic tierCoreTypeGTM or Marketing Partner
Description

Long-standing partnership with Thalassaemia International Federation to support TIF's coalition building efforts and patient advocacy. Agios has assisted TIF in establishing the first patient advocacy group for all hemolytic anemias. The partnership includes both hands-on collaboration and financial donations to advance TIF's mission of ensuring equal access to quality healthcare for every patient with thalassemia and other hemoglobin disorders worldwide.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioMarin is a direct peer as a rare disease-focused biopharmaceutical company with a portfolio of high-priced specialty enzyme replacement and gene therapies for ultra-rare conditions. Both companies operate with similar commercial models targeting small patient populations through specialty distribution, with comparable revenue scale and operating profiles.

TypeDirect peer
Description

Alnylam is a direct peer developing RNA interference (RNAi) therapeutics for rare diseases, with commercial products targeting conditions like hereditary ATTR amyloidosis. Both Agios and Alnylam operate as platform-based rare disease companies with premium-priced specialty therapies requiring specialized prescriber engagement.

3Global Blood Therapeutics (Pfizer)
TypeBroad incumbent
Description

Global Blood Therapeutics, acquired by Pfizer, developed Oxbryta for sickle cell disease before its voluntary withdrawal. Now operating within Pfizer, it represents a broad incumbent positioning in the sickle cell disease space where Agios' mitapivat is seeking accelerated approval.

4Bristol Myers Squibb
TypeBroad incumbent
Description

Bristol Myers Squibb is a broad incumbent in hematology with Reblozyl (luspatercept) approved for beta-thalassemia and MDS-related anemia, directly competing with Agios in the thalassemia market. As a large pharmaceutical company, BMS offers a wider portfolio but overlaps with Agios in the same hematology specialty channel and prescriber base.

TypeBroad incumbent
Description

Sobi is a broad incumbent rare disease company with a strong hematology portfolio including treatments for hemophilia, ITP, and other rare blood disorders. Sobi's established European rare disease commercial infrastructure and overlap in ITP (a key indication for Agios' cevidoplenib) makes it a comparable peer in the rare hematology space.

6bluebird bio
TypeDirect peer
Description

bluebird bio is a direct peer developing gene therapies for sickle cell disease (Lyfgenia) and beta-thalassemia, competing in the same hematology rare disease space. Both companies pursue disease-modifying therapies for inherited blood disorders through specialty channels with comparable patient identification and access challenges.

TypeDirect peer
Description

Vertex Pharmaceuticals is a direct peer focused on serious diseases with multiple approved therapies including Casgevy (exa-cel) gene therapy for sickle cell disease and beta-thalassemia. Both companies pursue rare hematology indications with high-cost specialty therapies and rely on specialized prescriber networks, making them highly comparable on business model and target market.

TypeEmerging player
Description

Disc Medicine is an emerging clinical-stage hematology company developing therapies for serious hematologic diseases including polycythemia vera and sickle cell disease. Both companies target rare blood disorders with novel mechanisms and operate in overlapping prescriber networks, though Disc Medicine is at an earlier commercial stage than Agios.

TypeDirect peer
Description

Alexion, acquired by AstraZeneca, pioneered rare disease commercialization with Soliris/Ultomiris for PNH and other complement-mediated conditions, including hematology indications. Agios CEO Brian Goff was recruited from Alexion, and the companies share highly comparable commercial models for ultra-rare hematology and specialty distribution.

TypeEmerging player
Description

Fulcrum Therapeutics is an emerging player developing therapies for sickle cell disease and other genetically defined diseases, with pociredil in late-stage development. Agios and Fulcrum co-sponsor the World Sickle Cell Day Marathon, indicating overlap in patient community engagement and competitive positioning in sickle cell disease.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Agios Pharmaceuticals

Rare Disease Pharmaceuticalsagios.com

Agios Pharmaceuticals is a biopharmaceutical company developing oral pyruvate kinase activators and related therapies for rare hemolytic anemias, including pyruvate kinase deficiency, thalassemia, and sickle cell disease. It commercializes PYRUKYND and AQVESME and pursues pipeline expansion via licensing and partnerships.

What Agios Pharmaceuticals does

Agios Pharmaceuticals is a publicly traded biopharmaceutical company (NASDAQ: AGIO) headquartered in Cambridge, Massachusetts, that develops oral therapies for rare hemolytic anemias and related rare diseases. After selling its oncology business to Servier for up to $2 billion in December 2020, the company pivoted to focus exclusively on cellular metabolism and rare blood disorders. Its commercial products — PYRUKYND and AQVESME, both formulations of the oral pyruvate kinase (PK) activator mitapivat — treat adults with pyruvate kinase deficiency (FDA-approved February 2022) and alpha- or beta-thalassemia (FDA-approved December 2025), respectively. The company's core scientific platform is built around PK activation, the mechanism by which mitapivat increases red blood cell ATP production, reduces 2,3-DPG levels, and improves red blood cell energy metabolism and lifespan in patients with hemolytic anemia.

The company's pipeline extends its cellular metabolism platform into adjacent indications, including tebapivat (a next-generation oral PK activator in Phase 2 for sickle cell disease and lower-risk MDS), cevidoplenib (an oral SYK inhibitor licensed from Oscotec in June 2026 for immune thrombocytopenia, with Phase 3 trials planned for H1 2028), AG-236 (an siRNA therapeutic targeting TMPRSS6 for polycythemia vera), and AG-181 (a phenylalanine hydroxylase stabilizer for phenylketonuria). Agios has also filed an sNDA seeking accelerated FDA approval for mitapivat in sickle cell disease, based on Phase 3 RISE UP data showing a 40.6% hemoglobin response rate versus 2.9% on placebo.

Agios generates revenue through direct U.S. product sales via specialty pharmacies and REMS-certified prescribers, supplemented by international royalty and milestone revenue from exclusive commercialization partners (Avanzanite Bioscience for 32 European countries and the UK/Switzerland; NewBridge Pharmaceuticals for the GCC region). AQVESME is priced at $425,000 per patient per year in the United States, with the U.S. thalassemia launch population estimated at approximately 4,000 patients and a global peak-year sales potential of $1 billion across multiple indications. Q1 2026 worldwide net product revenue was $20.7 million (up 138% year-over-year from $8.7 million), with 242 prescriptions written for AQVESME by quarter-end. The company ended Q1 2026 with $1.0 billion in cash and marketable securities against an annual operating cash burn of approximately $385 million.

Agios Pharmaceuticals firmographics

Firmographics
Name
Agios Pharmaceuticals
Legal name
Agios Pharmaceuticals, Inc.
Website
https://agios.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Agios Pharmaceuticals is a biopharmaceutical company developing oral pyruvate kinase activators and related therapies for rare hemolytic anemias, including pyruvate kinase deficiency, thalassemia, and sickle cell disease. It commercializes PYRUKYND and AQVESME and pursues pipeline expansion via licensing and partnerships.
Ownership category
akta.pro rank

Agios Pharmaceuticals industry classification

Industry
Product category
Rare Disease Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)

Keywords

  • Rare disease therapeutics
  • Hemolytic anemia treatments
  • Pyruvate kinase activators
  • Biopharmaceutical medicines
  • Cellular metabolism drugs

Where Agios Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Agios Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Product Sales (PYRUKYND/AQVESME): Agios generates revenue from direct product sales of mitapivat under two brand names: PYRUKYND for pyruvate kinase deficiency (approved in US 2022, EU 2022, UAE, KSA) and AQVESME for thalassemia (approved in US December 2025, EU May 2022). Revenue is generated through prescription sales via specialty pharmacies and healthcare providers, with 242 prescriptions written by Q1 2026.
  2. Licensing and Partnership Revenue: Agios receives milestone payments and royalties from commercial partners including Avanzanite Bioscience (Europe) and NewBridge Pharmaceuticals (GCC), who hold exclusive rights to commercialize mitapivat in their respective territories under revenue-sharing or royalty arrangements.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualAQVESME (mitapivat for thalassemia) - Annual wholesale pricing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Agios Pharmaceuticals product offering

Product offering

Core offering

Agios Pharmaceuticals develops and commercializes oral small-molecule therapeutics for rare hemolytic anemias, led by its first-in-class pyruvate kinase (PK) activator mitapivat marketed as PYRUKYND for pyruvate kinase deficiency and AQVESME for alpha- and beta-thalassemia. The company supplements these approved products with a pipeline of next-generation PK activators (tebapivat), a SYK inhibitor (cevidoplenib), an siRNA candidate (AG-236), and a PAH stabilizer (AG-181), supported by patient access programs such as MyAgios and the Global Managed Access Program.

Product overview

Agios Pharmaceuticals is a biopharmaceutical company developing a portfolio of therapies for rare diseases, particularly hemolytic anemias. The company's core approved products include PYRUKYND (mitapivat) for pyruvate kinase deficiency and AQVESME (mitapivat) for thalassemia, both oral pyruvate kinase activators that improve red blood cell energy metabolism. The pipeline includes next-generation candidates: Tebapivat (next-generation PK activator) for sickle cell disease and MDS, Cevidoplenib (SYK inhibitor) for immune thrombocytopenia, AG-236 for polycythemia vera, and AG-181 for phenylketonuria. Patient support services include the MyAgios program and Global Managed Access Program. The company leverages expertise in cellular metabolism to advance these rare disease therapies.

Differentiator

Problem solved

Functional benefit

Products and services

  • PYRUKYND (mitapivat) First-in-class oral pyruvate kinase (PK) activator approved for treating adults with pyruvate kinase deficiency. Increases ATP production and decreases 2,3-DPG in red blood cells to improve red blood cell energy metabolism and lifespan. Distributed in the U.S. through REMS-certified physicians and in Europe via Avanzanite Bioscience.
  • AQVESME (mitapivat) Oral pyruvate kinase activator approved by the FDA in December 2025 for treating anemia in adults with alpha- or beta-thalassemia; the only FDA-approved treatment for both non-transfusion-dependent and transfusion-dependent thalassemia. U.S. annual wholesale pricing is $425,000.
  • Tebapivat (AG-946) Next-generation oral pyruvate kinase activator in Phase 2 development for sickle cell disease and lower-risk myelodysplastic syndromes (MDS); designed as an improved follow-on to mitapivat.
  • Cevidoplenib Next-generation oral SYK inhibitor licensed from Oscotec for treating immune thrombocytopenia (ITP); Agios plans Phase 3 development in H1 2028 with peak US sales potential estimated at up to $1 billion.
  • MyAgios Patient Support Program Comprehensive patient support services program providing access support, prescription fulfillment, financial assistance, disease education, and community connections for eligible patients on Agios medicines, with dedicated Patient Support Managers.
  • Global Managed Access Program (GMAP) Program providing a pathway for patients to obtain access to PYRUKYND in countries where the medicine is not yet widely available, evaluating requests in consultation with qualified treating healthcare providers.

Quantifiable outcome

  • 138% year-over-year revenue growth in Q1 2026 ($20.7M vs $8.7M Q1 2025)
  • +6 more outcomes

Companies that use Agios Pharmaceuticals

Customer profile

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Agios Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Agios Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • Cayenne Wellness CenterminorGTM or Marketing Partner · 19 June 2026Co-hosting partnership for the 7th Annual 24-Hour World Sickle Cell Day Marathon on June 19, 2026, themed 'Closing the Survival Gap: Equity in Sickle Cell Care.' Agios serves as Advocate Sponsor alongside Community Sponsor Fulcrum Therapeutics. The virtual event brings together patients, caregivers, advocates, healthcare professionals, researchers, and policymakers to address disparities in diagnosis, treatment, and mental health services for sickle cell disease.
  • OscoteccoreStrategic or Co-development Partner · 1 June 2026Exclusive global license agreement with South Korea-based Oscotec to develop and commercialize cevidoplenib, a next-generation oral SYK inhibitor for treating immune thrombocytopenia (ITP). Agios paid $25 million upfront with potential additional payments of up to $140 million in development and regulatory milestones plus tiered royalties on future net sales. Agios assumes full responsibility for future development and commercialization costs, with plans to advance cevidoplenib into Phase 3 development for ITP in H1 2028. Peak US sales potential estimated at up to $1 billion.
  • Avanzanite Bioscience B.V.coreChannel Partner/ Reseller/ Distributor · 22 May 2026Exclusive partnership agreement with Amsterdam-based Avanzanite Bioscience B.V. for commercialization and distribution of PYRUKYND (mitapivat) across the European Economic Area, United Kingdom, and Switzerland. Avanzanite commercialized the drug following EU approval for thalassemia in May 2026. This is Avanzanite's fourth rare disease launch in Europe. The partnership was originally signed in June 2025.
  • NewBridge PharmaceuticalscoreChannel Partner/ Reseller/ DistributorPartnership with NewBridge Pharmaceuticals for commercialization of PYRUKYND in the Gulf Cooperation Council (GCC) region, covering Saudi Arabia and other GCC countries. The partnership was established to expand access to mitapivat in the Middle East market, pending regulatory approvals in those territories.
  • Global Alliance of Sickle Cell Disease Organizations (GASCDO)minorGTM or Marketing PartnerCo-hosting partnership with GASCDO for the 7th Annual 24-Hour World Sickle Cell Day Marathon, a free virtual event streamed live for 24 hours to address disparities in sickle cell disease care globally.
  • Thalassaemia International Federation (TIF)coreGTM or Marketing PartnerLong-standing partnership with Thalassaemia International Federation to support TIF's coalition building efforts and patient advocacy. Agios has assisted TIF in establishing the first patient advocacy group for all hemolytic anemias. The partnership includes both hands-on collaboration and financial donations to advance TIF's mission of ensuring equal access to quality healthcare for every patient with thalassemia and other hemoglobin disorders worldwide.

Scale indicators12 records

Recent moves9 records

Expansion highlights7 records

Agios Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • BioMarin Pharmaceutical: BioMarin is a direct peer as a rare disease-focused biopharmaceutical company with a portfolio of high-priced specialty enzyme replacement and gene therapies for ultra-rare conditions. Both companies operate with similar commercial models targeting small patient populations through specialty distribution, with comparable revenue scale and operating profiles.
  • Alnylam Pharmaceuticals: Alnylam is a direct peer developing RNA interference (RNAi) therapeutics for rare diseases, with commercial products targeting conditions like hereditary ATTR amyloidosis. Both Agios and Alnylam operate as platform-based rare disease companies with premium-priced specialty therapies requiring specialized prescriber engagement.
  • bluebird bio: bluebird bio is a direct peer developing gene therapies for sickle cell disease (Lyfgenia) and beta-thalassemia, competing in the same hematology rare disease space. Both companies pursue disease-modifying therapies for inherited blood disorders through specialty channels with comparable patient identification and access challenges.
  • Vertex Pharmaceuticals: Vertex Pharmaceuticals is a direct peer focused on serious diseases with multiple approved therapies including Casgevy (exa-cel) gene therapy for sickle cell disease and beta-thalassemia. Both companies pursue rare hematology indications with high-cost specialty therapies and rely on specialized prescriber networks, making them highly comparable on business model and target market.
  • Alexion (AstraZeneca Rare Disease): Alexion, acquired by AstraZeneca, pioneered rare disease commercialization with Soliris/Ultomiris for PNH and other complement-mediated conditions, including hematology indications. Agios CEO Brian Goff was recruited from Alexion, and the companies share highly comparable commercial models for ultra-rare hematology and specialty distribution.

Broad incumbents

  • Global Blood Therapeutics (Pfizer): Global Blood Therapeutics, acquired by Pfizer, developed Oxbryta for sickle cell disease before its voluntary withdrawal. Now operating within Pfizer, it represents a broad incumbent positioning in the sickle cell disease space where Agios' mitapivat is seeking accelerated approval.
  • Bristol Myers Squibb: Bristol Myers Squibb is a broad incumbent in hematology with Reblozyl (luspatercept) approved for beta-thalassemia and MDS-related anemia, directly competing with Agios in the thalassemia market. As a large pharmaceutical company, BMS offers a wider portfolio but overlaps with Agios in the same hematology specialty channel and prescriber base.
  • Swedish Orphan Biovitrum (Sobi): Sobi is a broad incumbent rare disease company with a strong hematology portfolio including treatments for hemophilia, ITP, and other rare blood disorders. Sobi's established European rare disease commercial infrastructure and overlap in ITP (a key indication for Agios' cevidoplenib) makes it a comparable peer in the rare hematology space.

Emerging players

  • Disc Medicine: Disc Medicine is an emerging clinical-stage hematology company developing therapies for serious hematologic diseases including polycythemia vera and sickle cell disease. Both companies target rare blood disorders with novel mechanisms and operate in overlapping prescriber networks, though Disc Medicine is at an earlier commercial stage than Agios.
  • Fulcrum Therapeutics: Fulcrum Therapeutics is an emerging player developing therapies for sickle cell disease and other genetically defined diseases, with pociredil in late-stage development. Agios and Fulcrum co-sponsor the World Sickle Cell Day Marathon, indicating overlap in patient community engagement and competitive positioning in sickle cell disease.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks1 record

Key highlights7 records

Customer concentration

Agios Pharmaceuticals social profiles

Digital presence

Agios Pharmaceuticals compliance and trust

Trust signal

Compliance2 records

Agios Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Agios Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles18 records

Agios Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Agios Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Agios Pharmaceuticals

What does Agios Pharmaceuticals do?

Agios Pharmaceuticals develops and commercializes oral small-molecule therapeutics for rare hemolytic anemias, led by its first-in-class pyruvate kinase (PK) activator mitapivat marketed as PYRUKYND for pyruvate kinase deficiency and AQVESME for alpha- and beta-thalassemia. The company supplements these approved products with a pipeline of next-generation PK activators (tebapivat), a SYK inhibitor (cevidoplenib), an siRNA candidate (AG-236), and a PAH stabilizer (AG-181), supported by patient access programs such as MyAgios and the Global Managed Access Program.

Is Agios Pharmaceuticals a public or private company?

Agios Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Agios Pharmaceuticals founded?

Agios Pharmaceuticals was founded in 2008. It employs 501 to 1,000 people.

Where is Agios Pharmaceuticals based?

Agios Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.

How does Agios Pharmaceuticals make money?

Two revenue lines are on record. Product Sales (PYRUKYND/AQVESME) is the primary driver. The others are licensing and Partnership Revenue.

Who are Agios Pharmaceuticals's main competitors?

Direct peers on record are BioMarin Pharmaceutical, Alnylam Pharmaceuticals, bluebird bio, Vertex Pharmaceuticals and Alexion (AstraZeneca Rare Disease). Broad incumbents are Global Blood Therapeutics (Pfizer), Bristol Myers Squibb and Swedish Orphan Biovitrum (Sobi). Emerging players are Disc Medicine and Fulcrum Therapeutics.

Does Agios Pharmaceuticals have an API?

No public API is recorded for Agios Pharmaceuticals.

What industry is Agios Pharmaceuticals in?

Agios Pharmaceuticals's product category is Rare Disease Pharmaceuticals. Its primary akta.pro industry code is HLAIACAI, Hematology Specialty Pharmaceuticals (Non-malignant). Its NAICS code is 3254 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewAgios Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $47, Implies 48% UpsideAnalysts' average price target for Agios Pharmaceuticals rose to $47 from $45.38, implying about 48% upside from the Nov. 12 close. The consensus remains a Buy across 10 analysts, with 7 Buys, 3 Holds, and no Sells.Simply Wall StIs Agios Pharmaceuticals (AGIO) Undervalued Following Stronger Q3 Results And Its FDA Review Update?Agios Pharmaceuticals reported stronger Q3 results and an FDA review extension for mitapivat in sickle cell disease. The stock is up 16.85% year-to-date but down 25.34% over one year, with a fair value of $46.00 versus a $31.76 close. The company faces ongoing net losses and flat 2026 spending.Seeking AlphaAgios Pharmaceuticals, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:AGIO) 2026-11-10Agios Pharmaceuticals reported Q3 2026 EPS of -$1.09, beating estimates by $0.14, and revenue of $55.39M, up 330% year-over-year, beating by $3.78M. The company's stock closed at $31.76, up 1.21%.Simply Wall StAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next YearAgios Pharmaceuticals reported Q3 revenue of $55M, beating estimates by 7.3%, with statutory losses of $1.09 per share. Analysts forecast 2027 revenue of $347.4M, a 147% increase, and a loss narrowing to $3.75 per share. The consensus price target of $45.88 remained unchanged.Seeking AlphaAgios Pharmaceuticals, Inc. (AGIO) Q3 2026 Earnings Call TranscriptAgios Pharmaceuticals held its Q3 2026 earnings call on November 5, 2026, with CEO Brian Goff and CFO Cecilia Jones. The call covered financial results and business highlights, with forward-looking statements included.TradingViewTruist Securities maintains Agios Pharmaceuticals at Buy, lowers price target to $35 from $37Truist Securities maintained Agios Pharmaceuticals at Buy and lowered its price target to $35 from $37, a 5.4% decrease. The price target implies an upside of 23.8% from the Nov 5 close of $28.27.BioSpaceAgios axes 100-plus R&D roles while awaiting FDA decisionAgios Pharmaceuticals is cutting over 35% of its R&D team, expecting $11 million in restructuring charges this year. The company expects savings from the 100-plus workforce reduction in 2027 and estimates a profit in 2028. The FDA delayed its mitapivat sickle cell decision to Feb. 1, 2027.Investing.comTruist cuts Agios Pharma stock price target on SCD concernsTruist Securities lowered its price target on Agios Pharmaceuticals to $35 from $37, citing sickle cell disease concerns. The stock trades at $28.38, down 15.7% over the past week. Truist maintains a Buy rating, noting Agios reported Q3 2026 EPS that missed expectations.TradingViewAgios Pharmaceuticals 3Q 2026: Revenue $55.39M, EPS ($1.09) — 10-Q SummaryAgios Pharmaceuticals reported Q3 2026 revenue of $55.39M, up 330% year over year, with a net loss of $65.05M, down 37.1% from the prior quarter. The increase was driven by AQVESME sales and lower R&D expenses, while the company initiated the phase 3 REIGNITE trial for mitapivat.Quiver QuantitativeAGIOS PHARMACEUTICALS ($AGIO) Releases Q3 2026 Earnings | AGIO Stock NewsAGIOS Pharmaceuticals reported Q3 2026 earnings of -$1.09 per share, beating estimates of -$1.25, and revenue of $55.39 million, beating estimates of $54.27 million. Insiders made four sales in the past six months, and analysts have set a median price target of $40.00.